{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:08:48Z","timestamp":1774278528230,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.vhri.2024.01.004","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T17:30:02Z","timestamp":1713979802000},"page":"100982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Cost-Effectiveness Analysis of Triptorelin, Goserelin, and Leuprolide in the Treatment of Patients With Metastatic Prostate Cancer: A Societal Perspective"],"prefix":"10.1016","volume":"42","author":[{"given":"Mehdi","family":"Rezaee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iman","family":"Karimzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Hashemi-Meshkini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahryar","family":"Zeighami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Bazyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Lotfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khosro","family":"Keshavarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.vhri.2024.01.004_bib1","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.vhri.2024.01.004_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15548627.2015.1100356","article-title":"Guidelines for the use and interpretation of assays for monitoring autophagy","volume":"12","author":"Klionsky","year":"2016","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.vhri.2024.01.004_bib3","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.vhri.2024.01.004_bib4","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ijc.33574","article-title":"Cancer in Iran 2008 to 2025: recent incidence trends and short-term predictions of the future burden","volume":"149","author":"Roshandel","year":"2021","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.vhri.2024.01.004_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a030361","article-title":"The epidemiology of prostate cancer","volume":"8","author":"Pernar","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"10.1016\/j.vhri.2024.01.004_bib6","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.vhri.2024.01.004_bib7","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2741\/1891","article-title":"Prostate cancer epidemiology","volume":"11","author":"Hsing","year":"2006","journal-title":"Front Biosci"},{"issue":"6","key":"10.1016\/j.vhri.2024.01.004_bib8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.eururo.2005.02.020","article-title":"Prostate cancer incidence in Guadeloupe, a French Caribbean archipelago","volume":"47","author":"Mallick","year":"2005","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.vhri.2024.01.004_bib9","first-page":"9","article-title":"Epidemiologic retrospective study of neoplasms of prostate gland in Birjand (South Khorasan province)","volume":"12","author":"Haghighi","year":"2005","journal-title":"J\u00a0Birjand Univ Med Sci"},{"issue":"4","key":"10.1016\/j.vhri.2024.01.004_bib10","first-page":"481","article-title":"The incidence of prostate cancer in Iran: results of a population-based cancer registry","volume":"10","author":"Sadjadi","year":"2007","journal-title":"Arch Iran Med"},{"issue":"2","key":"10.1016\/j.vhri.2024.01.004_bib11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.15171\/hpp.2019.13","article-title":"A\u00a0systematic review and meta-analysis on incidence of prostate cancer in Iran","volume":"9","author":"Moradi","year":"2019","journal-title":"Health Promot Perspect"},{"issue":"3","key":"10.1016\/j.vhri.2024.01.004_bib12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11864-011-0160-6","article-title":"Treating prostate cancer in elderly men: how does aging affect the outcome?","volume":"12","author":"Shelke","year":"2011","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.vhri.2024.01.004_bib13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2147\/CMAR.S148323","article-title":"Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study","volume":"9","author":"Restelli","year":"2017","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.vhri.2024.01.004_bib14","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1186\/s12913-020-05265-8","article-title":"The economic burden of prostate cancer \u2014 a Swedish prevalence-based register study","volume":"20","author":"Hao","year":"2020","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"10.1016\/j.vhri.2024.01.004_bib15","first-page":"139","article-title":"Economic burden of prostate cancer in Iran: measuring costs and quality of life","volume":"10","author":"Foroughi Moghadam","year":"2019","journal-title":"Middle East J Cancer"},{"issue":"10","key":"10.1016\/j.vhri.2024.01.004_bib16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.4140\/TCP.n.2016.581","article-title":"Therapy update for metastatic castration-resistant prostate cancer","volume":"31","author":"Dinh","year":"2016","journal-title":"Consult Pharm"},{"issue":"126","key":"10.1016\/j.vhri.2024.01.004_bib17","first-page":"602","article-title":"[Treatment of clinically localized prostate cancer. Part III\u2014external beam radiotherapy]","volume":"21","author":"Gisterek","year":"2006","journal-title":"Pol Merkur Lek"},{"issue":"6","key":"10.1016\/j.vhri.2024.01.004_bib18","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.eururo.2017.06.035","article-title":"Quality of life outcomes after primary treatment for clinically ocalized prostate cancer: a systematic review","volume":"72","author":"Lardas","year":"2017","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.vhri.2024.01.004_bib19","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2217\/fon.13.65","article-title":"Recent advances revolutionize treatment of metastatic prostate cancer","volume":"9","author":"Madan","year":"2013","journal-title":"Future Oncol"},{"issue":"5","key":"10.1016\/j.vhri.2024.01.004_bib20","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.eururo.2015.04.036","article-title":"Treatment of the primary tumor in metastatic prostate cancer: current concepts and future perspectives","volume":"69","author":"Bayne","year":"2016","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.vhri.2024.01.004_bib21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.eururo.2016.09.040","article-title":"Mortality among men with advanced prostate cancer excluded from the ProtecT trial","volume":"71","author":"Johnston","year":"2017","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.vhri.2024.01.004_bib22","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2016.5983","article-title":"Surrogate end points for all-cause mortality in men with localized unfavorable-risk prostate cancer treated with radiation therapy vs radiation therapy plus androgen deprivation therapy: a secondary analysis of a randomized clinical trial","volume":"3","author":"Royce","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.vhri.2024.01.004_bib23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev.med.45.1.391","article-title":"Gonadotropin-releasing hormone and its analogs","volume":"45","author":"Conn","year":"1994","journal-title":"Annu Rev Med"},{"issue":"4","key":"10.1016\/j.vhri.2024.01.004_bib24","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1517\/13543784.10.4.709","article-title":"LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action","volume":"10","author":"Limonta","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"10.1016\/j.vhri.2024.01.004_bib25","first-page":"291","article-title":"Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer","volume":"13","author":"Shahidi","year":"2001","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"3","key":"10.1016\/j.vhri.2024.01.004_bib26","article-title":"Cost-Effectiveness Analysis of triptorelin versus leuprolide in the Treatment of Advanced Prostate Cancer","volume":"3","author":"Ravasio","year":"2016","journal-title":"Glob Reg Health Technol Assess"},{"issue":"2","key":"10.1016\/j.vhri.2024.01.004_bib27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1586\/erp.13.13","article-title":"Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer","volume":"13","author":"Hatoum","year":"2013","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"8","key":"10.1016\/j.vhri.2024.01.004_bib28","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1464-410X.2011.10434.x","article-title":"Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer","volume":"109","author":"Lu","year":"2012","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.vhri.2024.01.004_bib29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jval.2010.10.023","article-title":"Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy","volume":"14","author":"Iannazzo","year":"2011","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.vhri.2024.01.004_bib30","first-page":"688","article-title":"Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone na\u00efve prostate cancer","volume":"37","author":"Ramamurthy","year":"2019","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"6","key":"10.1016\/j.vhri.2024.01.004_bib31","article-title":"Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective","volume":"26","author":"Zheng","year":"2017","journal-title":"Eur J Cancer Care"},{"issue":"1","key":"10.1016\/j.vhri.2024.01.004_bib32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1586\/14737167.2014.873703","article-title":"Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus","volume":"14","author":"Petrou","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"10.1016\/j.vhri.2024.01.004_bib33","first-page":"135","article-title":"Estimation social discount rate for Iran","volume":"10","author":"Abdoli","year":"2009","journal-title":"Econ Res Rev"},{"issue":"1","key":"10.1016\/j.vhri.2024.01.004_bib34","first-page":"107","article-title":"On discount rates for economic evaluations in global health","volume":"35","author":"Haacker","year":"2020","journal-title":"Health Policy Plan"},{"issue":"4","key":"10.1016\/j.vhri.2024.01.004_bib35","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10198-007-0078-x","article-title":"Decision-analytical modelling in health-care economic evaluations","volume":"9","author":"Sun","year":"2008","journal-title":"Eur J Health Econ HEPAC Health Econ Prev Care"},{"issue":"4","key":"10.1016\/j.vhri.2024.01.004_bib36","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10198-021-01271-7","article-title":"Adjusted productivity costs of stroke by human capital and friction cost methods: a Northern Finland Birth Cohort 1966 study","volume":"22","author":"Rissanen","year":"2021","journal-title":"Eur J Health Econ HEPAC Health Econ Prev Care"},{"issue":"9","key":"10.1016\/j.vhri.2024.01.004_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238643","article-title":"Economic burden of the persistent morbidity of nodding syndrome on caregivers in affected households in Northern Uganda","volume":"15","author":"Latio","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vhri.2024.01.004_bib38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clinthera.2018.11.001","article-title":"Estimating the cost of illness of prostate cancer in Iran","volume":"41","author":"Mojahedian","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.vhri.2024.01.004_bib41","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.vhri.2019.01.007","article-title":"Valuation of quality weights for EuroQol 5-dimensional health states with the time trade-off method in the capital of Iran","volume":"18","author":"Goudarzi","year":"2019","journal-title":"Value Health Reg Issues"},{"issue":"9","key":"10.1016\/j.vhri.2024.01.004_bib42","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.37435","article-title":"A\u00a0cost-utility and cost-effectiveness analysis of different oral antiviral medications in patients with HBeAg-negative chronic hepatitis B in Iran: an economic microsimulation decision model","volume":"16","author":"Keshavarz","year":"2016","journal-title":"Hepat Mon"},{"issue":"2","key":"10.1016\/j.vhri.2024.01.004_bib43","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost-effectiveness of interventions: alternative approaches","volume":"93","author":"Marseille","year":"2015","journal-title":"Bull World Health Organ"},{"issue":"3","key":"10.1016\/j.vhri.2024.01.004_bib45","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1078-1439(02)00242-9","article-title":"A\u00a0cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer","volume":"21","author":"Samant","year":"2003","journal-title":"Urol Oncol"},{"issue":"12","key":"10.1016\/j.vhri.2024.01.004_bib46","first-page":"634","article-title":"[Direct and indirect costs of luteinising hormone-releasing hormone analogues in the treatment of locally advanced or metastatic prostate cancer in Italy]","volume":"106","author":"Fadda","year":"2015","journal-title":"Recenti Prog Med"},{"issue":"4","key":"10.1016\/j.vhri.2024.01.004_bib47","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4111\/icu.2019.60.4.244","article-title":"Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: goserelin\u00a0versus triptorelin versus leuprolide","volume":"60","author":"Shim","year":"2019","journal-title":"Investig Clin Urol"},{"issue":"3","key":"10.1016\/j.vhri.2024.01.004_bib48","first-page":"848","article-title":"Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence","volume":"185","author":"Lawrentschuk","year":"2011","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.vhri.2024.01.004_bib49","first-page":"233","article-title":"A\u00a0cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom","volume":"17","author":"Lee","year":"2014","journal-title":"J\u00a0Med Econ"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109924000128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109924000128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:33:21Z","timestamp":1762605201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109924000128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":46,"alternative-id":["S2212109924000128"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2024.01.004","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Triptorelin, Goserelin, and Leuprolide in the Treatment of Patients With Metastatic Prostate Cancer: A Societal Perspective","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2024.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100982"}}